Review of the article "Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients", verified by Publons, Web of Science
Чланак у часопису (Рецензирана верзија)
Метаподаци
Приказ свих података о документуАпстракт
Objective: To investigate the linical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients.
Methods: A total of 168 mild to moderate hypertension outpatients were randomized to treatment with different anti-hypertensive measures. The subjects were divided into the Diltiazem Group (90mg/d, n=35), RASI Group (150mg/d irbesartan or 10mg/d perindopril, n=45) and CT Group (150mg/d irbesartan + 90mg/d diltiazem or 10mg/d perindopril + 90mg/d diltiazem, n=88). Subjects took examinations of the systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular mass index (LVMI), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), and total ischemia burden (TIB) level before and after treatment during the 6 to 18 months follow-up.
Results: The level of IVST/LVPWT/LVMI in three groups decreased after treatment. SBP, DBP, IVST, LVPWT, and LVMI were decreased significantly after the treatment o...f RASI (p<0.05). Especially, the post-treatment LVMI in the CT group was significantly lower than that of the Diltiazem Group, but the post-treatment results of LVMI in the CT group and RASI group were not statistically different (P>0.05). TIB of patients in the CT group and Diltiazem Group decreased at all times before and after treatment, and that the difference in TIB of patients in the RASI Group had no statistical significance (p>0.05).
Conclusions: RASI combined with diltiazem can attenuate left ventricular hypertrophy as compared with diltiazem or RASI alone.
Извор:
Current Pharmaceutical Analysis, 2021, 1/BMS-CPA-2021-145-18Колекције
Институција/група
Mašinski fakultetTY - JOUR AU - Jovanović, Tamara PY - 2021 UR - https://machinery.mas.bg.ac.rs/handle/123456789/5812 AB - Objective: To investigate the linical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients. Methods: A total of 168 mild to moderate hypertension outpatients were randomized to treatment with different anti-hypertensive measures. The subjects were divided into the Diltiazem Group (90mg/d, n=35), RASI Group (150mg/d irbesartan or 10mg/d perindopril, n=45) and CT Group (150mg/d irbesartan + 90mg/d diltiazem or 10mg/d perindopril + 90mg/d diltiazem, n=88). Subjects took examinations of the systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular mass index (LVMI), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), and total ischemia burden (TIB) level before and after treatment during the 6 to 18 months follow-up. Results: The level of IVST/LVPWT/LVMI in three groups decreased after treatment. SBP, DBP, IVST, LVPWT, and LVMI were decreased significantly after the treatment of RASI (p<0.05). Especially, the post-treatment LVMI in the CT group was significantly lower than that of the Diltiazem Group, but the post-treatment results of LVMI in the CT group and RASI group were not statistically different (P>0.05). TIB of patients in the CT group and Diltiazem Group decreased at all times before and after treatment, and that the difference in TIB of patients in the RASI Group had no statistical significance (p>0.05). Conclusions: RASI combined with diltiazem can attenuate left ventricular hypertrophy as compared with diltiazem or RASI alone. T2 - Current Pharmaceutical Analysis T1 - Review of the article "Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients", verified by Publons, Web of Science EP - 18 SP - 1/BMS-CPA-2021-145 UR - https://hdl.handle.net/21.15107/rcub_machinery_5812 ER -
@article{ author = "Jovanović, Tamara", year = "2021", abstract = "Objective: To investigate the linical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients. Methods: A total of 168 mild to moderate hypertension outpatients were randomized to treatment with different anti-hypertensive measures. The subjects were divided into the Diltiazem Group (90mg/d, n=35), RASI Group (150mg/d irbesartan or 10mg/d perindopril, n=45) and CT Group (150mg/d irbesartan + 90mg/d diltiazem or 10mg/d perindopril + 90mg/d diltiazem, n=88). Subjects took examinations of the systolic blood pressure (SBP), diastolic blood pressure (DBP), left ventricular mass index (LVMI), interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), and total ischemia burden (TIB) level before and after treatment during the 6 to 18 months follow-up. Results: The level of IVST/LVPWT/LVMI in three groups decreased after treatment. SBP, DBP, IVST, LVPWT, and LVMI were decreased significantly after the treatment of RASI (p<0.05). Especially, the post-treatment LVMI in the CT group was significantly lower than that of the Diltiazem Group, but the post-treatment results of LVMI in the CT group and RASI group were not statistically different (P>0.05). TIB of patients in the CT group and Diltiazem Group decreased at all times before and after treatment, and that the difference in TIB of patients in the RASI Group had no statistical significance (p>0.05). Conclusions: RASI combined with diltiazem can attenuate left ventricular hypertrophy as compared with diltiazem or RASI alone.", journal = "Current Pharmaceutical Analysis", title = "Review of the article "Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients", verified by Publons, Web of Science", pages = "18-1/BMS-CPA-2021-145", url = "https://hdl.handle.net/21.15107/rcub_machinery_5812" }
Jovanović, T.. (2021). Review of the article "Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients", verified by Publons, Web of Science. in Current Pharmaceutical Analysis, 1/BMS-CPA-2021-145-18. https://hdl.handle.net/21.15107/rcub_machinery_5812
Jovanović T. Review of the article "Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients", verified by Publons, Web of Science. in Current Pharmaceutical Analysis. 2021;:1/BMS-CPA-2021-145-18. https://hdl.handle.net/21.15107/rcub_machinery_5812 .
Jovanović, Tamara, "Review of the article "Clinical effect of Perindopril or irbesartan combined with diltiazem moderate primary hypertension outpatients", verified by Publons, Web of Science" in Current Pharmaceutical Analysis (2021):1/BMS-CPA-2021-145-18, https://hdl.handle.net/21.15107/rcub_machinery_5812 .